...
首页> 外文期刊>Journal of Leukocyte Biology: An Official Publication of the Reticuloendothelial Society >IL-27 inhibits pathophysiological intraocular neovascularization due to laser burn
【24h】

IL-27 inhibits pathophysiological intraocular neovascularization due to laser burn

机译:IL-27抑制激光烧伤引起的病理生理性眼内新血管形成

获取原文
   

获取外文期刊封面封底 >>

       

摘要

AMD is the most common disease leading to acquired blindness in developed countries. CNV is the foremost cause of AMD and is thought to be induced by regional inflammation as a result of age-related conformational changes of the chorioretinal interface. Here, we show that IL-27, a member of the IL-6/IL-12 cytokine family, has an angiostatic effect and regulates the development of laser-induced experimental CNV in mice. In this model, IL-27 expression increased in the damaged choroid and peaked at the 24 h-time-point. IL-27 neutralization, induced by inoculating an antagonistic antibody into the vitreous cavity, enhanced VEGF production and the extent of CNV. By contrast, the administration of rIL-27 reduced VEGF production and the extent of CNV. Mice deficient in the EBI3, which lack IL-27, also showed more CNV than C57BL/6 mice, and this was reduced by IL-27 supplementation. We additionally investigated the effect of IL-27 on the function of macrophages, which play a critical role in CNV. IL-27 did not affect macrophage migration but inhibited its VEGF production. IL-27 therefore appears to regulate CNV and is a promising candidate target for treating sight-threatening diseases caused by ocular neovascularization.
机译:在发达国家,AMD是导致后天失明的最常见疾病。 CNV是AMD的最主要病因,并被认为是脉络膜视网膜界面与年龄相关的构象变化的结果,是由区域性炎症引​​起的。在这里,我们显示IL-6 / IL-12细胞因子家族的成员IL-27具有血管抑制作用,并调节小鼠激光诱导的实验CNV的发育。在该模型中,IL-27的表达在受损的脉络膜中增加,并在24小时的时间点达到峰值。通过在玻璃体腔中接种拮抗抗体而诱导的IL-27中和作用增强了VEGF的产生和CNV的程度。相比之下,rIL-27的给药减少了VEGF的产生和CNV的程度。缺乏IL-27的EBI3缺陷小鼠也显示出比C57BL / 6小鼠更多的CNV,并且通过补充IL-27可以减少这种情况。我们还研究了IL-27对巨噬细胞功能的影响,巨噬细胞在CNV中起关键作用。 IL-27不会影响巨噬细胞的迁移,但会抑制其VEGF的产生。因此,IL-27似乎可以调节CNV,并且是治疗由眼新血管形成引起的视力障碍疾病的有希望的候选靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号